AUA 2014

auaAmerican Urological Association (AUA)
Annual Meeting
May 16 - 21, 2014

Orlando, Florida USA

#AUA14 - Prevalence of and impact of health-significant comorbidities in Caucasian-European men presenting for primary couple’s infertility-results of a cross-sectional survey - Session Highlights

ORLANDO, FL USA (UroToday.com) - Lower general health status is often associated with male factor infertility. In this AUA presentation, Dr. Michele Colichhia presented her group’s efforts to study the prevalence of the impact of infertility on comorbidities in a population of European men.

#AUA14 - Mood disorders among men with non-obstructive azoospermia: A prospective analysis - Session Highlights

ORLANDO, FL USA (UroToday.com) - It is well known that infertility and efforts to reintroduce new mechanisms for pregnancy causes significant distress in patients. In this AUA 2014 presentation, Dr. Aaron Bernie presented on their prospective study in which they assessed the relationship of anxiety and depression in men who were evaluated for non-obstructive azoospermia (NOA)

#AUA14 - Klinefelter’s syndrome: An under diagnosed and under treated cause of male infertility - Session Highlights

ORLANDO, FL USA (UroToday.com) - Klinefelter’s syndrome (KS) is considered to be the most common cause of genetic male infertility. Dr. Daniel T. Oberlin hypothesized in their study that KS is not well diagnosed and it may be associated with co-morbidities that need medical attention. They presented on their finding during this poster presentation.

#AUA14 - Renal percutaneous access with the Uro Dyna-CT - Session Highlights

ORLANDO, FL USA (UroToday.com) - Percutaneous renal access can be challenging in complex cases with large stone burden (i.e., staghorn calculi) or a special kidney anatomy.

#AUA14 - Direct endoscopic visualization with combined ultrasound guided access during percutaneous nephrolithotomy – a feasibility study and comparison to conventional cohort - Session Highlights

ORLANDO, FL USA (UroToday.com) - Access in PCNL cases remains challenging. The study group presented a novel approach combining direct ureteroscopic visualization of access location with ultrasound guidance. They aimed to compare outcomes in patients with US-guided percutaneous renal access to conventional fluoroscopic guided access.

#AUA14 - Does hypertension impact 24-hour urine parameters in patients with nephrolithiasis? - Session Highlights

ORLANDO, FL USA (UroToday.com) - There is a known association between hypertension (HTN) and nephrolithiasis. Abnormalities in renal calcium metabolism in hypertensive patients can lead to increased urinary calcium excretion. The research group sought to evaluate differences in 24-hour urine parameters between patients with and without HTN in a large cohort of stone formers.

#AUA14 - Targeted magnetic resonance imaging/ultrasound fusion biopsy is a significantly better predictor of total prostate cancer tumor volume than random 12-core biopsy - Session Highlights

ORLANDO, FL USA (UroToday.com) - Tumor volume is an important prognostic factor for men with prostate cancer, yet it has proven difficult to measure pre-operatively.

#AUA14 - Bilateral multifocal papillary type I renal cell carcinoma: Clinical characteristics and association with chronic renal insufficiency - Session Highlights

ORLANDO, FL USA (UroToday.com) - Bilateral multifocal (BMF) papillary type I renal cell carcinoma (RCC) has traditionally been associated with hereditary papillary renal cell carcinoma (HPRC) with mutations of the met proto-oncogene.

#AUA14 - Utilization of sacrocolpopexy: Comparison of practice patterns between urologists and gynecologists using a national database - Session Highlights

ORLANDO, FL USA (UroToday.com) - Dr. Aaron Weinberg presented his results of a comparison of national practice patterns between urologists and gynecologists in the utilization of abdominal sacrocolpopexy (ASC).

#AUA14 - Further characterization of the effects of prior or no prior docetaxel therapy on CRPC patients with bone metastases receiving Ra-223 in the phase 3 ALSYMPCA trial - Session Highlights

ORLANDO, FL USA (UroToday.com) - During the “Advanced Prostate Cancer II” session, Dr. Neal Shore presented further data from the ALSYMPCA trial.